Sagar Lonial, MD, FACP, provides a look at an upcoming Virtual Tumor Board program on BCMA-directed therapies in relapsed/refractory multiple myeloma treatment.
Real-World RRMM Data Explore Dose Deescalation and Outpatient Use of Teclistamab
November 18th 2024During a Case-Based Roundtable® event, Hana Safah, MD, examined several real-world studies of dose frequency and outpatient administration of teclistamab in patients with multiple myeloma in the first article of a 2-part series.
Read More